Novartis AG (NVSEF)
OTCMKTS
· Delayed Price · Currency is USD
109.60
0.00 (0.00%)
Oct 29, 2024, 4:00 PM EDT
Novartis AG Revenue
Novartis AG had revenue of $13.17B in the quarter ending September 30, 2024, with 8.93% growth. This brings the company's revenue in the last twelve months to $49.94B, up 8.92% year-over-year. In the year 2023, Novartis AG had annual revenue of $46.66B with 7.36% growth.
Revenue (ttm)
49.94B
Revenue Growth
+8.92%
P/S Ratio
n/a
Revenue / Employee
656.61K
Employees
76,057
Market Cap
220.13B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.69B |
Ryman Healthcare Limited | 411.39M |
Verano Holdings Corp. | 920.97M |
Vireo Growth Inc. | 98.04M |
Medexus Pharmaceuticals Inc. | 108.78M |
Novartis AG News
- 1 day ago - Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile - GlobeNewsWire
- 1 day ago - Novartis AG (NVS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Novartis Posts Results Above Estimates, Raises Outlook - Investopedia
- 1 day ago - Novartis Lifts Guidance Again After Key Drugs Help Results - WSJ
- 2 days ago - Novartis: we are exploring obesity drugs but other areas provide growth for years - Reuters
- 2 days ago - Novartis lifts 2024 guidance for 3rd time on wider use of its drugs - Reuters
- 2 days ago - Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance - GlobeNewsWire
- 2 days ago - Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash - Seeking Alpha